BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23344579)

  • 1. Wilms' tumor 1 protein and estrogen receptor beta expression are associated with poor outcomes in uterine carcinosarcoma.
    Guntupalli SR; Cao D; Shroff R; Gao F; Menias C; Stewart Massad L; Powell MA; Mutch DG; Thaker PH
    Ann Surg Oncol; 2013 Jul; 20(7):2373-9. PubMed ID: 23344579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
    Dickson EL; Vogel RI; Gehrig PA; Pierce S; Havrilesky L; Secord AA; Dottino J; Fader AN; Ricci S; Geller MA
    Gynecol Oncol; 2015 Nov; 139(2):275-82. PubMed ID: 26348313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma.
    Tanner EJ; Leitao MM; Garg K; Chi DS; Sonoda Y; Gardner GJ; Barakat RR; Jewell EL
    Gynecol Oncol; 2011 Dec; 123(3):548-52. PubMed ID: 21945551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
    Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
    Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wilms tumor gene 1 (WT1) is a prognostic marker in high-grade uterine sarcoma.
    Coosemans A; Van Calster B; Verbist G; Moerman P; Vergote I; Van Gool SW; Amant F
    Int J Gynecol Cancer; 2011 Feb; 21(2):302-8. PubMed ID: 21734473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors and status of hormone receptors and angiogenic factors in uterine carcinosarcoma.
    Etoh T; Nakai H
    J Obstet Gynaecol Res; 2014 Mar; 40(3):820-5. PubMed ID: 24320058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
    Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
    Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.
    Seagle BL; Kanis M; Kocherginsky M; Strauss JB; Shahabi S
    Gynecol Oncol; 2017 Apr; 145(1):71-77. PubMed ID: 28317560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
    Zhu J; Wen H; Bi R; Wu X
    J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
    Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
    Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
    Pacaut C; Bourmaud A; Rivoirard R; Moriceau G; Guy JB; Collard O; Bosacki C; Jacquin JP; Levy A; Chauleur C; Magné N; Merrouche Y
    Am J Clin Oncol; 2015 Jun; 38(3):272-7. PubMed ID: 23751320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Black race independently predicts worse survival in uterine carcinosarcoma.
    Erickson BK; Doo DW; Zhang B; Huh WK; Leath CA
    Gynecol Oncol; 2014 May; 133(2):238-41. PubMed ID: 24613675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles.
    Ioffe YJ; Li AJ; Walsh CS; Karlan BY; Leuchter R; Forscher C; Cass I
    Gynecol Oncol; 2009 Dec; 115(3):466-71. PubMed ID: 19767065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy and prognosis in uterine carcinosarcoma.
    Chiang CY; Huang HJ; Chang WY; Yang LY; Wu RC; Wang CC; Tung HJ; Chao A; Lai CH
    J Formos Med Assoc; 2021 Nov; 120(11):1977-1987. PubMed ID: 33992491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years.
    Matsuo K; Ross MS; Yunokawa M; Johnson MS; Machida H; Omatsu K; Klobocista MM; Im DD; Satoh S; Baba T; Ikeda Y; Bush SH; Hasegawa K; Blake EA; Takekuma M; Shida M; Nishimura M; Adachi S; Pejovic T; Takeuchi S; Yokoyama T; Ueda Y; Iwasaki K; Miyake TM; Yanai S; Nagano T; Takano T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
    Surg Oncol; 2019 Jun; 29():25-32. PubMed ID: 31196490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic features of surgical stage I uterine carcinosarcoma.
    Ferguson SE; Tornos C; Hummer A; Barakat RR; Soslow RA
    Am J Surg Pathol; 2007 Nov; 31(11):1653-61. PubMed ID: 18059221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.
    Matsuo K; Takazawa Y; Ross MS; Elishaev E; Podzielinski I; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Matsuzaki S; Baba T; Satoh S; Shida M; Nishikawa T; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Fujiwara K; Hazama Y; Kadogami D; Moffitt MN; Takeuchi S; Nishimura M; Iwasaki K; Ushioda N; Johnson MS; Yoshida M; Hakam A; Li SW; Richmond AM; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Yamaguchi K; Oishi T; Kajiwara H; Hasegawa K; Yasuda M; Kawana K; Suda K; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Wakatsuki A; Sugiyama T; Pejovic T; Nagano T; Shimoya K; Andoh M; Shiki Y; Enomoto T; Sasaki T; Fujiwara K; Mikami M; Shimada M; Konishi I; Kimura T; Post MD; Shahzad MM; Im DD; Yoshida H; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
    Ann Oncol; 2016 Jul; 27(7):1257-66. PubMed ID: 27052653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma.
    Desai NB; Kollmeier MA; Makker V; Levine DA; Abu-Rustum NR; Alektiar KM
    Gynecol Oncol; 2014 Oct; 135(1):49-53. PubMed ID: 25084509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma.
    Leitao MM; Hensley ML; Barakat RR; Aghajanian C; Gardner GJ; Jewell EL; O'Cearbhaill R; Soslow RA
    Gynecol Oncol; 2012 Mar; 124(3):558-62. PubMed ID: 22085894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
    Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
    Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.